Ephedra Research III: Government Hearings and Investigations

The blue star indicates particularly interesting material; editor's comments are in Arial font gray text.

Index of Hearings on Ephedra

• House Committee on Energy and Commerce, Index of Documents Related to Ephedra Investigation
• House Committee on Energy and Commerce, Issues Relating to Ephedra-Containing Dietary Supplements, 23/24 July 2003
• House Committee on Energy and Commerce, Issues Relating to Ephedra-Containing Dietary Supplements, 23/24 July 2003 (pdf version containing attachments)
• Ephedra: Who is Protecting the American Consumers? Hearing before the Oversight of Government Management, Restructuring, and the District of Columbia Subcommittee of the Committee on Governmental Affairs, United States Senate, One Hundred Seventh Congress, Second Session, October 8, 2002
• Adverse Event Reports from Metabolife Minority Staff Report, Special Investigations Division, Committee on Government Reform, U.S. House of Representatives (October 2002)
• When Diets Turn Deadly: Consumer Safety and Weight-loss Supplements Hearing Before The Oversight of Government Management, Restructuring, and The District Of Columbia Subcommittee of The Committee On Governmental Affairs, United States Senate, One Hundred Seventh Congress, Second Session, July 31, 2002
• Diet, Physical Activity, Dietary Supplements, Lifestyle And Health Hearing Before The Committee On Government Reform House Of Representatives, One Hundred Seventh Congress, Second Session, July 25, 2002
• Swindlers, Hucksters And Snake Oil Salesman: Hype And Hope Marketing Anti-Aging Products To Seniors Hearing Before The Special Committee On Aging United States Senate, One Hundred Seventh Congress, First Session, September 10, 2001
• Six Years After The Establishment Of DSHEA: The Status Of National and International Dietary Supplement Research and Regulation Hearing Before The Committee On Government Reform House Of Representatives, One Hundred Seventh Congress, First Session, March 20, 2001

House Committee on Energy & Commerce (2003-07-23)

• Exhibit 104 - FDA Memorandum of Interview of Steven Heymsfield MD (Provides information on the study performed by Dr. Carol Boozer ST&T Consultants, Metabolife International Inc., and others) 10/18/2001
• Exhibit 113 – HHS Memo containing the Special Government Expert Reviews of the Boozer-Daly Study. 5/14/2003
• Exhibit 106 – Email: from Carlon Colker to David Brown. About a study that Colker was conducting for Metabolife. Small mix-up regarding the bottles that the samples arrived in (all said Metabolife when should have been blank) 9/10/2002
• Exhibit 93 – Letter from David Humann to Dirk Aschmoneit. Discusses cost and availability of different sources of caffeine for the product 11/3/1999
• Exhibit 94 – Handwritten notes on the ingredients 11/17/1999
• Exhibit 95 – Letter from David Humann to Dirk Aschmoneit. Includes a list of other ingredients and their quantities 11/22/1999
• Exhibit 96 – FDA Memo re: Office of Post marketing Drug Risk Assessment (OPDRA) Analysis of Adverse Event Reports for Ephedrine Alkaloid-Containing Dietary Supplements (EADS). 3/28/2000
• Exhibit 97 – DOJ Press release on the fining and sentencing of James Cameron, manufacturer of Formula One. 7/7/2000

Cytodyne Technologies – Xenadrine Labels

• Exhibit 45 Dated 1/03
• Exhibit 46 Dated 10/01
• Exhibit 47 Dated 7/01
• Exhibit 48 Dated 8/99
• Exhibit 49 Dated 7/99
• Exhibit 50 Dated 6/99
• Exhibit 51 Dated 8/98

top

Last Updated: 2005-02-26

If you find the information on this page helpful, please support CIRCARE with a tax-deductible contribution today. Help us advocate for meaningful protection of human subjects in research. Donating on-line with PayPal is quick and easy - find out more on our Support page.

---